I believe the market has sorted out the risk reward ratios between AEGR and ISIS on their respective FH drugs, mipomersen (ISIS) versus lomitapide (AEGR), and has decided that AEGR's drug may capture most of the market for FH. There is a significant risk in that Mipo will not get approved by the FDA without more data (it was a 9-6 committee vote with one self-described "weak yes") versus Lomitapide which had a 13-2 vote as a result of its efficacy and better safety profile. This is why AEGR continues to climb (two analysts came out with $30 PT's after the decision), while ISIS continues to fall since the committee vote. I said it would be $25 by last Monday, but it obviously will take longer. The fact that we are hitting $22 today is very encouraging to me, however. We have another $4-5 bounce on approval in two months.